Skip to content
Open access

Serial Tumor-Agnostic Plasma Profiling with a Compact NGS Panel During First-Line Therapy for Newly Diagnosed Metastatic Colorectal Cancer.

Oct 2026 · International Journal of Molecular Sciences · Vol 27 21, pp. 9633 · 0 citations · 31 references
Medicine

TL;DR

Compact tumor-agnostic plasma sequencing provides complementary molecular information, but its clinical utility requires further validation.

Abstract

Plasma circulating tumor DNA (ctDNA) profiling may complement tissue hotspot testing and reveal molecular changes during treatment of metastatic colorectal cancer (mCRC). We prospectively studied 39 patients with newly diagnosed unresectable mCRC receiving first-line therapy. Cell-free DNA was collected before treatment and after two and four cycles and analyzed using a 10 kb, 10-gene hybrid-capture sequencing panel with molecular barcodes and error correction. Baseline oncogenic variants were detected in 32 of 35 evaluable patients (91.4%). Compared with routine tissue PCR for shared RAS/BRAF targets, plasma testing showed 84.2% sensitivity (16/19) and 100% specificity (19/19) in the intention-to-test cohort, compared with 88.2% sensitivity (15/17) and 100% specificity (17/17) among technically evaluable samples. Three activating KRAS variants (L19F, A59T, and A146T) lay outside the tissue assays' target regions; patients carrying these alterations received anti-EGFR therapy. Patients with metastases in two or more organs had more detectable oncogenic alterations than those with one metastatic site (median, three versus two; adjusted q = 0.00184; rank-biserial correlation = 0.687). Serial sampling revealed divergent trajectories of individual variants in nine patients. Early reductions in plasma variant allele frequencies tended to be greater among partial responders, although associations with radiological response were not significant after multiple testing correction. Compact tumor-agnostic plasma sequencing provides complementary molecular information, but its clinical utility requires further validation.

Read PDF

Similar papers

Open access Oct 2026

Validation of a ctDNA-Based comprehensive genomic profiling panel (IST80 Plus) for advanced non-small cell lung cancer

Circulating tumor DNA (ctDNA) profiling can complement tissue testing in advanced non-small-cell lung cancer (NSCLC), particularly when tissue is unavailable or unable to capture tumor heterogeneity. We evaluated the analytical and clinical performance of Illumina Solid Tumor Panel 80 (IST80 Plus), a focused hybrid-cap...

P. Mediavilla-Medel, R. Serna-Blasco, Lucía Robado de Lope et al. · 0 citations
Open access Nov 2026

Tissue and Plasma NGS Are Complementary for Molecular Profiling in Advanced Non-Small Cell Lung Cancer: Real-World Concordance and Clinical Impact

Background: Comprehensive molecular profiling is increasingly important in advanced non-small cell lung cancer (NSCLC), but the integration of tissue- and plasma-based next-generation sequencing (NGS) and its real-world therapeutic impact remain uncertain. Methods: We conducted a retrospective single-center study of 20...

Ana Gómez Rueda, P. Garrido-López, L. Pekarek et al. · 0 citations
Oct 2026

B-088 Comprehensive Genomic Profiling of Solid Tumors by Next Generation Sequence : Clinical Utility and Biomarker Discovery in a Pan-Cancer Cohort

The transition from single-gene testing to comprehensive genomic profiling (CGP) is essential for precision oncology. The next generation sequence platform, enables the simultaneous detection of diverse variants and complex immuno-oncology biomarkers, providing a holistic view of the tumor genomic landscape....

Chung-Gue Huang, Shu-Li Yang, Chang-Fu Kuo et al. · 0 citations
Open access Oct 2026

Whole-genome sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors

Abstract Background Circulating tumor DNA (ctDNA) assays can transform patient management by enabling molecular residual disease (MRD) detection, prognosis prediction, and treatment monitoring. Here, we report clinical performance of Signatera Genome, a whole-genome sequencing (WGS)-based ctDNA assay, in a diverse pan-...

Mridula A. George, Gary S. Schwartz, W. McHayleh et al. · 0 citations
Open access Oct 2026

Real-world plasma-based next-generation sequencing findings in metastatic lung adenocarcinoma: a single-center retrospective study

Plasma-based NGS identifies clinically relevant genomic alterations in metastatic lung adenocarcinoma and complementstissue-based molecular testing in routine practice in a real-world setting.

E. Kocaaslan, Emir Göçer, Fırat Akagündüz et al. · 0 citations
Review Oct 2026

Serial circulating tumour DNA monitoring in first-line advanced NSCLC (COPE): a randomized, two-arm non-comparative phase II trial.

PURPOSE COPE evaluated serial circulating tumor DNA (ctDNA) profiling with molecular tumor board (MTB) review during first-line therapy for advanced non-small cell lung cancer (NSCLC). EXPERIMENTAL DESIGN COPE was a multicenter, randomized (2:1), noncomparative phase II trial. Arm A underwent serial plasma profiling...

Candice Francheska B. Tambaoan, Letuan Phan, S. Cousin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.